Drugs / Laninamivir
Laninamivir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05648448 | Feb 2023 → Jan 2027 expected | influenza | University of Oxford | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2016-08-26 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir® Dry Powder Inhaler 20mg daiichisankyo.com ↗
These additional dosage regimen approvals make it possible to administer single inhalation doses of this drug to adults and children for the prevention of influenza virus infection. |
| 2013-12-20 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Approval for the Use of Inavir® to Prevent Influenza daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) for the prevention of influenza in both adults and children. |
| 2012-11-15 | Daiichi Sankyo | Regulatory Daiichi Sankyo Submits Application for Approval to Manufacture and Market Inavir(R) Dry Powder Inhaler, an Influenza Antiviral for the Prevention of Influenza in Japan daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it has submitted an application for a partial label change in Japan to manufacture and market the influenza antiviral product Inavir® Dry Powder Inhaler (laninamivir octanoate hydrate) for prevention of influenza infection. |
| 2012-08-22 | Daiichi Sankyo | Results Positive Phase 3 Clinical Study Results for Inavir(R) Dry Powder Inhaler, an Influenza Antiviral, for the Prevention of Influenza daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the influenza antiviral product Inavir® Dry Powder Inhaler (laninamivir octanoate hydrate) significantly reduced the incidence of influenza infection compared to placebo in a phase 3 clinical study. |
| 2010-09-10 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Approval to Manufacture and Market Inavir(R) Influenza Antiviral Inhalant for Treatment in Japan daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has received approval in Japan to manufacture and market Inavir® Dry Powder Inhaler 20mg, for treatment of influenza that is a laninamivir octanoate hydrate prodrug. |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Laninamivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05648448 ↗ |
| Known as | INAVIR | “Laninamivir (INAVIR®)” NCT05648448 ↗ |
| Known as | R-125489 | ChEMBL registry synonym — accepted as the source's own label CHEMBL466246 ↗ |
| Modality | Small molecule | — CHEMBL466246 ↗ |
| Route | Inhaled | “Inhaled laninamivir” NCT05648448 ↗ |